tradingkey.logo

Veracyte Inc

VCYT
View Detailed Chart
42.350USD
+0.650+1.56%
Close 11/10, 16:00ETQuotes delayed by 15 min
3.35BMarket Cap
110.40P/E TTM

Veracyte Inc

42.350
+0.650+1.56%
Intraday
1m
30m
1h
D
W
M
D

Today

+1.56%

5 Days

+16.19%

1 Month

+21.70%

6 Months

+42.54%

Year to Date

+6.94%

1 Year

+16.09%

View Detailed Chart

TradingKey Stock Score of Veracyte Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Veracyte Inc's Score

Industry at a Glance

Industry Ranking
19 / 407
Overall Ranking
94 / 4611
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 13 analysts
Buy
Current Rating
46.182
Target Price
+10.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Veracyte Inc Highlights

StrengthsRisks
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 50.32% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 109.39, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 87.37M shares, decreasing 1.63% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 4.47M shares of this stock.

Veracyte Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Veracyte Inc Info

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Ticker SymbolVCYT
CompanyVeracyte Inc
CEOMr. Marc A. Stapley
Websitehttps://www.veracyte.com/
KeyAI